ES2062155T3 - Composiciones para el tratamiento de neoplasia que contienen un agente antineoplasico y un agente protector reductor de efectos secundarios. - Google Patents

Composiciones para el tratamiento de neoplasia que contienen un agente antineoplasico y un agente protector reductor de efectos secundarios.

Info

Publication number
ES2062155T3
ES2062155T3 ES90107246T ES90107246T ES2062155T3 ES 2062155 T3 ES2062155 T3 ES 2062155T3 ES 90107246 T ES90107246 T ES 90107246T ES 90107246 T ES90107246 T ES 90107246T ES 2062155 T3 ES2062155 T3 ES 2062155T3
Authority
ES
Spain
Prior art keywords
side effects
treatment
agent
antineoplastic
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90107246T
Other languages
English (en)
Inventor
Ardalan Bach
William R Shanahan Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Application granted granted Critical
Publication of ES2062155T3 publication Critical patent/ES2062155T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE DESCRIBE UNA COMBINACION DE QUIMIOTERAPIA PARA TRATAMIENTO DE ENFERMEDADES NEOPLASICAS. LOS EFECTOS COLATERALES CITOTOXICOS ADVERSOS ASOCIADOS CON AGENTES ANTI-NEOPLASICOS SE PUEDEN REDUCIR POR EL USO DE UN COPOLIMERO CITOPROTECTOR EN COMBINACION CON EL AGENTE ANTI-NEOPLASICO. UNA COMBINACION PREFERIDA DE QUIMIOTERAPIA USA DOXORUBICINA PARA CONSEGUIR LA REDUCCION DEL TUMOR CON UN AGENTE CITOPROTECTOR PARA REDUCIR LOS EFECTOS TOXICOS COLATERALES ASOCIADOS CON LA DOXORUBICINA Y PARA MEJORAR LA ACTIVIDAD ANTI-NEOPLASICA DE LA DOXORUBICINA.
ES90107246T 1989-04-17 1990-04-17 Composiciones para el tratamiento de neoplasia que contienen un agente antineoplasico y un agente protector reductor de efectos secundarios. Expired - Lifetime ES2062155T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33950389A 1989-04-17 1989-04-17

Publications (1)

Publication Number Publication Date
ES2062155T3 true ES2062155T3 (es) 1994-12-16

Family

ID=23329296

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90107246T Expired - Lifetime ES2062155T3 (es) 1989-04-17 1990-04-17 Composiciones para el tratamiento de neoplasia que contienen un agente antineoplasico y un agente protector reductor de efectos secundarios.

Country Status (8)

Country Link
EP (1) EP0393575B1 (es)
JP (1) JPH02292227A (es)
AT (1) ATE102838T1 (es)
CA (1) CA2014732A1 (es)
DE (1) DE69007319T2 (es)
DK (1) DK0393575T3 (es)
ES (1) ES2062155T3 (es)
PT (1) PT93772A (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9213077D0 (en) * 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
US5371199B1 (en) * 1992-08-14 1995-12-26 Univ Pennsylvania Substituted porphyrins porphyrin-containing polymers and synthetic methods therefor
US5817830A (en) * 1992-08-14 1998-10-06 Trustees Of The University Of Pennsylvania Pyrrolic compounds
US5599924A (en) * 1992-08-14 1997-02-04 Trustees Of The University Of Pennsylvania Electron-deficient porphyrins and processes and intermediates for preparing same
US5493017A (en) * 1992-08-14 1996-02-20 The Trustees Of The University Of Pennsylvania Ring-metalated porphyrins
US5378456A (en) * 1993-03-25 1995-01-03 American Cyanamid Company Antitumor mitoxantrone polymeric compositions
US5569667A (en) * 1995-01-19 1996-10-29 Warner-Lambert Company Treatment of prostate cancer
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
US6265385B1 (en) 1996-01-11 2001-07-24 Topo Target Aps Topoisomerase II poison and bis-dioxopiperazine derivative combination therapy
EP0874630B1 (en) * 1996-01-11 2003-08-20 TopoTarget ApS Topoisomerase ii poison and bis-dioxypiperazine derivative combination therapy
ATE310505T1 (de) * 1996-05-14 2005-12-15 Stanislaw R Burzynski Liposomale antineoplaston therapie mit bemerkenswert verbesserter antineoplastischer aktivität
DE19636889A1 (de) 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
US5783689A (en) * 1996-11-12 1998-07-21 University Of Notre Dame Antibacterial and antifungal nucleosides
GB9804013D0 (en) 1998-02-25 1998-04-22 Sanofi Sa Formulations
US6767926B1 (en) 1999-10-12 2004-07-27 Temple University - Of The Commonwealth System Of Higher Education Method for protecting normal cells from cytotoxicity of chemotherapeutic agents
AU780844B2 (en) * 1999-10-12 2005-04-21 Temple University-Of The Commonwealth System Of Higher Education Method for protecting normal cells from cytotoxicity of chemotherapeutic agents
AT408719B (de) * 2000-03-22 2002-02-25 Nowicky Wassili Mittel zur behandlung von hepatitis c
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
US20020128258A1 (en) * 2001-03-09 2002-09-12 Jean-Pierre Robin Therapeutical method involving subcutaneous administration of drugs containing cephalotaxine derivatives
US8563592B2 (en) 2001-11-01 2013-10-22 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods
AU2002350115A1 (en) 2001-11-01 2003-05-12 Spectrum Pharmaceuticals, Inc. Medical compositions for intravesical treatment of bladder cancer
EP1463487B1 (en) * 2001-12-19 2010-05-19 Research Development Foundation Liposomal delivery of vitamin e based compounds
JP2005532280A (ja) 2002-04-03 2005-10-27 アストラゼネカ アクチボラグ 化合物
FR2863892B1 (fr) * 2003-12-18 2007-05-11 Univ Paris Descartes Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux
WO2005111055A1 (ja) * 2004-04-28 2005-11-24 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai 新規抗生物質キガマイシン類とその用途
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
EP3431142B1 (en) 2011-08-30 2020-06-17 Astex Pharmaceuticals, Inc. Decitabine derivative formulations
WO2014179528A2 (en) * 2013-05-01 2014-11-06 Brown Dennis M Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions
AU2016287585B2 (en) 2015-07-02 2020-12-17 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
RU2020108580A (ru) 2017-08-03 2021-09-03 Оцука Фармасьютикал Ко., Лтд. Лекарственное соединение и способы его очистки
CN116019798B (zh) * 2022-07-20 2024-03-12 中南大学湘雅二医院 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4255537A (en) * 1979-01-22 1981-03-10 Monsanto Company Polymeric immunoregulatory agents containing half-amide/half carboxy/imide groups

Also Published As

Publication number Publication date
CA2014732A1 (en) 1990-10-17
EP0393575A1 (en) 1990-10-24
DE69007319T2 (de) 1994-08-04
JPH02292227A (ja) 1990-12-03
DE69007319D1 (de) 1994-04-21
DK0393575T3 (da) 1994-04-05
PT93772A (pt) 1991-01-08
ATE102838T1 (de) 1994-04-15
EP0393575B1 (en) 1994-03-16

Similar Documents

Publication Publication Date Title
ES2062155T3 (es) Composiciones para el tratamiento de neoplasia que contienen un agente antineoplasico y un agente protector reductor de efectos secundarios.
EP2295063A3 (en) Compositions and the use thereof the treatment of mitochondrial diseases
EP1370253B8 (en) Use of alpha, beta unsaturated aryl sulfones for protecting cells and tissues from ionizing radiation toxicity
PT671910E (pt) Utilizacao de derivados de adamantano no fabrico de um medicamento para o tratamento do glaucoma
SE9301951D0 (sv) Methods for administration of taxol
MX9306924A (es) Composiciones antitumorales que contienen derivados de taxano.
CO4410203A1 (es) Formulaciones de analogos de insulina
IT1073647B (it) Perfezionamento nei materiali di medicazione in particolare bende costituite da tre componenti,per l'applicazione sulla superficie di un corpo
ATE298577T1 (de) Präparate auf purinbasis
EP0690722A4 (en) COMPOSITION AND METHOD FOR REDUCING THE TOXICITY OF BIOLOGICALLY ACTIVE FACTORS
EP0668933A4 (en) USE OF METHIONINASE AS AN ANTI-TUMOR MEDICINE IN ANTIMETHIONIN CHEMOTHERAPY.
ES2036553T3 (es) Composiciones farmaceuticas que tienen actividad antineoplastica.
WO2003049694A3 (en) Methods of therapy for non-hodgkin's lymphoma
PL313223A1 (en) Nigella sativa as a therapeutic agent
ES2062375T3 (es) Composiciones farmaceuticas que contienen un complejo de zinc.
MX9205568A (es) Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida.
GR3027569T3 (en) Glycosyl-etoposide prodrugs, process for their preparation and their use in combination with functionalised tumour-specific enzyme conjugates
ITRM910730A1 (it) Composizioni farmaceutiche, per uso topico, contenenti "scavengers" di radicali liberi dell'ossigeno e antibatterici, indicate nella terapia dei tessuti superficiali.
BE1000723A4 (fr) Utilisation de gangliosides exogenes dans des maladies tumorales comme facteur de protection contre la toxicite de medicaments antitumoraux.
DE3163920D1 (en) Pharmaceutical preparations comprising polyprenyl compounds, especially as anti-cancer agents, and pharmaceutical compositions for the prevention and treatment of cancer and skin diseases
ES2031462T3 (es) Procedimiento para producir 1-b-d-arabinofuranosilcitosina-5'-estearilfosfato monosodico y monohidrato de la misma, y compuesto farmaceutico que contiene esta ultima.
KR870010871A (ko) 재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법
JPS55113721A (en) Immunity regulator
BE894860A (fr) Therapeutique adjuvante par agent progestatif
EP1374873B8 (en) The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for supressing side-effect of radiotherapy and chemotherapy

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 393575

Country of ref document: ES